Sumain Faisal

FDA Delays Approval For Ultragenyx’s Gene Therapy, But Not A Dealbreaker, Says Analyst

Ultragenyx’s UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline. Latest Ratings for RARE Date Firm Action From To Feb 2022 Morgan Stanley Maintains Overweight Feb 2022 JP Morgan Upgrades Neutral Overweight Feb 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for RARE View the…

Read More